Yarlagadda S. Babu
2021
Compensation breakdown
| Bonus | $18,358 |
|---|---|
| Non-Equity Incentive Plan | $206,525 |
| Option Awards | $1,287,761 |
| Salary | $458,945 |
| Stock Awards | $400,050 |
| Other | $14,500 |
| Total | $2,386,139 |
Babu received $1.3M in option awards, accounting for 54% of the total pay in 2021.
Babu also received $18.4K in bonus, $206.5K in non-equity incentive plan, $458.9K in salary, $400.1K in stock awards and $14.5K in other compensation.
Rankings
In 2021, Yarlagadda S. Babu's compensation ranked 5,343rd out of 12,415 executives tracked by ExecPay. In other words, Babu earned more than 57.0% of executives.
| Classification | Ranking | Percentile |
|---|---|---|
All | 5,343 out of 12,415 | 57th |
Division Manufacturing | 2,248 out of 5,505 | 59th |
Major group Chemicals And Allied Products | 979 out of 2,375 | 59th |
Industry group Drugs | 871 out of 2,096 | 58th |
Industry Biological Products, Except Diagnostic Substances | 214 out of 449 | 52nd |
Pay ratio
| Yarlagadda S. Babu's Pay | $2,386,139 |
|---|---|
| Median Employee's Pay | $273,522 |
| Pay Ratio | 9to 1 |
In 2021, the annual total compensation of Yarlagadda S. Babu was $2,386,139.
The annual total compensation of the median employee at BioCryst Pharmaceuticals was $273,522.
The ratio of Yarlagadda S. Babu's pay to the pay of median employee was therefore 9 to one.
Babu's colleagues
We found five more compensation records of executives who worked with Yarlagadda S. Babu at BioCryst Pharmaceuticals in 2021.
2021
Megan Sniecinski
BioCryst Pharmaceuticals
Former Chief Business Officer
2021
Jon Stonehouse
BioCryst Pharmaceuticals
Chief Executive Officer
2021
Helen Thackray
BioCryst Pharmaceuticals
Chief R&D Officer
2021
Anthony Doyle
BioCryst Pharmaceuticals
Chief Financial Officer
2021
William Sheridan
BioCryst Pharmaceuticals